DMAC

3.65

6.41% -0.25

Dopo l'orario di chiusura: 3.65

Diamedica Therapeutics Inc (DMAC)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$3.90

Aprire:

$3.85

Volume 24 ore:

112.71K

Relative Volume:

1.14

Capitalizzazione di mercato:

$177.54M

Reddito:

Utile/perdita netta:

$-19.90M

Rapporto P/E:

-6.8868

EPS:

-0.53

Flusso di cassa netto:

$-19.80M

1 W Prestazione:

-11.84%

1M Prestazione:

-8.29%

6M Prestazione:

-32.16%

1 anno Prestazione:

+55.32%

Intervallo 1D:

$3.645

$3.94

Intervallo di 1 settimana:

$3.645

$4.275

Portata 52W:

$2.14

$6.8184

Diamedica Therapeutics Inc Stock (DMAC) Company Profile

Nome

Diamedica Therapeutics Inc

Settore

Healthcare (1168)

Industria

Biotechnology (661)

Telefono

(763) 496-5454

Indirizzo

301 CARLSON PARKWAY, MINNEAPOLIS, MN

Dipendente

Cinguettio

@diamedica

Prossima data di guadagno

2025-03-17

Ultimi documenti SEC

DMAC's Discussions on Twitter

Confronta DMAC con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
DMAC Diamedica Therapeutics Inc	3.65	177.54M	0	-19.90M	-19.80M	-0.53
VRTX Vertex Pharmaceuticals Inc	455.45	115.69B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	529.24	53.25B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	307.99	39.22B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	577.89	35.78B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	269.63	27.68B	3.81B	-644.79M	-669.77M	-6.24

Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-10-07	Iniziato	H.C. Wainwright	Buy
2024-04-24	Ripresa	Craig Hallum	Buy
2023-06-22	Aggiornamento	Oppenheimer	Perform → Outperform
2021-04-09	Iniziato	Oppenheimer	Outperform
2021-02-17	Iniziato	ROTH Capital	Buy
2020-10-30	Iniziato	Guggenheim	Buy
2020-07-08	Iniziato	Maxim Group	Buy
2019-04-30	Iniziato	Dougherty & Company	Buy
2019-03-05	Iniziato	Lake Street	Buy

Mostra tutto

Diamedica Therapeutics Inc Borsa (DMAC) Ultime notizie

Jun 10, 2025

Millennium Management LLC Increases Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World

Jun 10, 2025

Jun 05, 2025

42,212 Shares in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Purchased by Jane Street Group LLC - Defense World

Jun 05, 2025

Jun 04, 2025

Can DiaMedica Deliver A Breakthrough In Preeclampsia Treatment? - RTTNews

Jun 04, 2025

Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Increases By 38.3% - Defense World

Jun 04, 2025

May 30, 2025

Lake Street Keeps Their Buy Rating on Diamedica Therapeutics (DMAC) - The Globe and Mail

May 30, 2025

Northern Trust Corp Has $978,000 Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World

May 30, 2025

DMAC: HC Wainwright & Co. Reiterates Buy Rating with $10 Price T - GuruFocus

May 30, 2025

DiaMedica Therapeutics’ (DMAC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

May 30, 2025

May 29, 2025

H.C. Wainwright holds DiaMedica stock Buy rating, $10 target - Investing.com

May 29, 2025

H.C. Wainwright holds DiaMedica stock Buy rating, $10 target By Investing.com - Investing.com India

May 29, 2025

May 28, 2025

Transcript : DiaMedica Therapeutics Inc.Special Call - marketscreener.com

May 28, 2025

With 39% ownership, DiaMedica Therapeutics Inc. (NASDAQ:DMAC) insiders have a lot riding on the company's future - Yahoo Finance

May 28, 2025

May 22, 2025

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025 - BioSpace

May 22, 2025

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025 | DMAC Stock News - GuruFocus

May 22, 2025

May 20, 2025

14,581 Shares in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Purchased by Balyasny Asset Management L.P. - Defense World

May 20, 2025

May 19, 2025

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on D - GuruFocus

May 19, 2025

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia - Business Wire

May 19, 2025

Research Analysts Offer Predictions for DMAC FY2025 Earnings - Defense World

May 19, 2025

May 18, 2025

Equities Analysts Offer Predictions for DMAC FY2029 Earnings - Defense World

May 18, 2025

May 17, 2025

DiaMedica targets preeclampsia Phase 2 dose selection and ReMEDy2 interim analysis in H1 2026 as enrollment momentum builds - MSN

May 17, 2025

May 16, 2025

Analysts Offer Insights on Healthcare Companies: Organon (OGN), Diamedica Therapeutics (DMAC) and Nkarta (NKTX) - The Globe and Mail

May 16, 2025

Craig-Hallum Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC) - The Globe and Mail

May 16, 2025

DiaMedica Therapeutics reports annual meeting results By Investing.com - Investing.com Nigeria

May 16, 2025

May 15, 2025

DiaMedica Therapeutics reports annual meeting results - Investing.com

May 15, 2025

DiaMedica Elects Directors at Annual Meeting - TipRanks

May 15, 2025

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2025 Earnings Call Transcript - Insider Monkey

May 15, 2025